These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 2434223)

  • 1. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.
    Maxwell SA; Kurzrock R; Parsons SJ; Talpaz M; Gallick GE; Kloetzer WS; Arlinghaus RB; Kouttab NM; Keating MJ; Gutterman JU
    Cancer Res; 1987 Mar; 47(6):1731-9. PubMed ID: 2434223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphotyrosine phosphatase activity prevents the detection of P210bcr/abl protein in mature cells in chronic myelogenous leukemia even by an immunoblotting technique.
    Shibata K; Nishimura J; Takahira H; Nawata H
    Leukemia; 1989 Sep; 3(9):615-9. PubMed ID: 2474729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel 53 kDa protein complexed with P210bcr-abl in human chronic myelogenous leukemia cells.
    Li WJ; Kloetzer WS; Arlinghaus RB
    Oncogene; 1988 Jun; 2(6):559-66. PubMed ID: 3133627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of P210bcr-abl in mature granulocytes from Ph1-positive chronic myelogenous leukemia patients by an immunoblotting method.
    Kuwao F; Takahashi I
    Leukemia; 1993 Aug; 7(8):1168-73. PubMed ID: 8350617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
    Wetzler M; Talpaz M; Van Etten RA; Hirsh-Ginsberg C; Beran M; Kurzrock R
    J Clin Invest; 1993 Oct; 92(4):1925-39. PubMed ID: 8408645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
    Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two bcr/abl fusion gene products, P210bcr/abl and P190bcr/abl, are equally sensitive to the protein tyrosine phosphatase of mature granulocytes.
    Nishimura J; Okamura J; Shibata K; Takahira H; Yufu Y; Kato S; Hirata J; Umemura T; Nawata H
    Int J Hematol; 1991 Dec; 54(6):471-8. PubMed ID: 1793829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia.
    Kaur G; Gazit A; Levitzki A; Stowe E; Cooney DA; Sausville EA
    Anticancer Drugs; 1994 Apr; 5(2):213-22. PubMed ID: 8049505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line.
    Carlesso N; Griffin JD; Druker BJ
    Oncogene; 1994 Jan; 9(1):149-56. PubMed ID: 8302574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia].
    Okabe M
    Hokkaido Igaku Zasshi; 1993 Mar; 68(2):237-50. PubMed ID: 8509066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
    Danhauser-Riedl S; Warmuth M; Druker BJ; Emmerich B; Hallek M
    Cancer Res; 1996 Aug; 56(15):3589-96. PubMed ID: 8758931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
    Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
    Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia.
    Guo JQ; Hirsch-Ginsberg CF; Xian YM; Stass SA; Champlin RE; Giralt SA; McCredie KB; Campbell ML; Arlinghaus RB
    Hematol Pathol; 1993; 7(2):91-106. PubMed ID: 8340287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphotyrosine antibodies identify the p210c-abl tyrosine kinase and proteins phosphorylated on tyrosine in human chronic myelogenous leukemia cells.
    Naldini L; Stacchini A; Cirillo DM; Aglietta M; Gavosto F; Comoglio PM
    Mol Cell Biol; 1986 May; 6(5):1803-11. PubMed ID: 2431286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.
    Deininger MW; Vieira S; Mendiola R; Schultheis B; Goldman JM; Melo JV
    Cancer Res; 2000 Apr; 60(7):2049-55. PubMed ID: 10766197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphism of the human c-abl gene: relation to incidence and course of chronic myelogenous leukemia.
    Daniel L; Ahmed CM; Bloodgood RS; Kidd JR; Castiglione CM; Duttagupta S; Lebowitz P
    Oncogene; 1987 May; 1(2):193-200. PubMed ID: 2894000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.
    Ren SY; Xue F; Feng J; Skorski T
    Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
    Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV
    Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the hybrid P210 bcr/abl protein in Philadelphia chromosome positive B-lymphoid cell lines.
    Stacchini A; Ponzetto C; Guerrasio A; Martinotti G; Rege Cambrin G; Scaravaglio P; Rosso C; Piacibello W; Aglietta M; Saglio G
    Haematologica; 1989; 74(3):249-54. PubMed ID: 2511093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.